In paroxysmal nocturnal hemoglobinuria (PNH), impaired glycosyl-phosphatidylinositol (PI)-anchoring of membrane proteins such as decay-accelerating factor has been known to lead to increased susceptibility to complement. Moreover, abnormal expression of non-PI-anchoring glycoproteins such as C3b/C4b receptor (CR1) or glycophorin-a also has been shown in PNH. Therefore, we biochemically analyzed glycosphingolipids (GSL) as one of the membrane glycoconjugates of PNH erythrocytes. Erythrocytes of all seven PNH patients showed altered expression of sialosyl GSL (gangliosides) as compared with the control erythrocytes of healthy donors.
Introduction
Paroxysmal nocturnal hemoglobinuria (PNH)' is an acquired hemolytic disease with an increased sensitivity of erythrocytes to the lytic action ofcomplement (1, 2) . This abnormal susceptibility to complement has been partly explained by a deficiency in decay-accelerating factor (DAF) (3, 4) or C8-binding protein (5) , which are glycosyl-phosphatidylinositol (PI)-anchored proteins in the erythrocyte membrane (6, 7) . Therefore, many studies are now being conducted on the abnormal process involving PI-anchoring of the membrane proteins (8) . But the exact mechanism of the process is still unknown. On the other hand, membrane disorders other than the PI-anchoring ofproteins have already been pointed out, i.e., the abnormality of C3b/C4b receptor (CR1) glycoprotein (9) or glycophorin-a (10) in PNH erythrocytes. The altered expression of membrane glycoconjugates such as glycosyl-PI (glyceroglycolipids) or glycoproteins raises the possibility of abnormal expression of other glycoconjugates like glycosphingolipids (GSL). 2 GSL are well known to participate in various membranerelated biological functions (1 1, 12) . Since the expression of GSL is regulated indirectly by genes through the expression of metabolic enzymes, GSL change in association with cell growth, ontogenesis, cell differentiation, and transformation. GSL in human erythrocytes are also well characterized (13, 14) and have important functions, such as blood group antigens (11, 12) . Therefore, we have focused on the expression of membrane GSL in PNH erythrocytes to determine new features of membrane disorders in PNH.
Methods
Patient profile. The clinical features ofseven PNH patients are summarized in Table I . Patient 1 had an inherited deficiency of the ninth component of complement (C9). Because she had never experienced spontaneous massive hemolysis nor required any blood transfusions, PNH erythrocytes were abundant in her peripheral blood. Patient 2 had moderate hemolytic attacks, but never required any blood transfusions because his anemia was mild. Patients 3 and 4 had experienced massive hemolytic attacks and required frequent blood transfusions. Patients 5, 6, and 7 had mild hemolysis but did not require any blood transfusions.
Chemicals. All organic solvents were of analytical grade. DEAESephadex A-25 was obtained from Pharmacia Fine Chemicals, Uppsala, Sweden, and was converted to its acetate form as described previously (15). Iatrobeads (activated silicic acid, 6RS-8060) were purchased from latron Laboratories Inc., Tokyo, Japan (16) . Precoated high-performance thin-layer plates (Silica Gel 60, 0.25 mm thick) and Polygram sil G plates were purchased from E. Merck, Darmstadt, FRG, and Macherey-Nagel, Duren, FRG, respectively. The following standard glycolipids were prepared in our laboratory: II3NeuAc-LacCer (GM3), II3NeuAc-Gg3Cer (GM2), II3NeuAc-Gg4Cer (GMI), IV3NeuAc,II3NeuAc-Gg4Cer (GD1a), 113(NeuAc)2-g4Cer (GDlb), and IV3NeuAc,113(NeuAc)2-Gg4Cer (GTIb) from bovine brain; II3(NeuAc)2-LacCer (GD3) from human milk; IV3NeuAc-nLc4Cer from human erythrocytes; and IV3NeuAc-Lc4Cer and IV6NeuAc-nLc4Cer from human meconium. nLc4Cer and Lc4Cer were prepared from IV3NeuAc-nLc4Cer and IV3NeuAc-Lc4Cer by treatment with neuraminidase, respectively. Gg4Cer (GAl) was prepared from GM, using formic acid (17 was performed by latrobead column chromatography. TLC. TLC of GSL was performed with the following solvent systems: C/M/W (60:40:10 vol/vol/vol) for neutral GSL; and C/M/0.5% aqueous CaC12 (50:50:12 vol/vol/vol) for gangliosides. Neutral GSL and gangliosides were located with orcinol-H2SO4 and resorcinol-HCI reagents, respectively. The distribution oflipid-bound sialic acid in the individual gangliosides on TLC plates was quantitated densitometrically with a dual wave-length TLC densitometer (CS-9000; Shimadzu Co., Kyoto, Japan) as described previously (18, 19) .
Structural elucidation of gangliosides from human erythrocytes.
,B-Galactosidase, with a specificity reacting to ,B14 linkage but not to ,B1-3 linkage, was prepared from the culture medium of Diplococcus pneumoniae as described previously (20) . Neuraminidase ( Vibrio cholerae; Behring, Marburg, FRG) and the #-galactosidase were used for structural determination as described before (18, 20) . In brief, gangliosides were incubated in 100 yd ofdistilled water at 37°C for 2 h with 20 mU of the neuraminidase. Products were then treated with the ft-galactosidase in 50 Ml of 200 mM phosphate buffer (pH 6.5) containing 5 Mg of sodium deoxycholate. The reaction products were examined by TLC. Gangliosides and their degradates were further analyzed by TLCimmunostaining (21) with a mouse MAb (Y916 MAb) that recognized the terminal NeuAca2-6Gal structure of gangliosides (21), a human MAb (HMST-1) which reacted with Lc4Cer (21), a mouse anti-GM3 MAb donated from MECT Co., Tokyo, Japan, or a rabbit anti-GAI antibody (22) . Fast atom bombardment mass spectrometry (FAB-MS) was also used for structural determination (23) .
Compositions of fatty acid and sphingosine (long chain base) of purified gangliosides were determined by gas-liquid chromatography as described previously (18, 24) .
Quantitative determination of membrane constituents. Protein in the starting material was determined by the method of Bradford (25).
Lipid-bound sialic acid and lipid-bound phosphorus in the total lipid extracts were determined by the resorcinol-HCI (26) and Bartlett's methods, respectively (27).
Immunofluorescence staining oferythrocytes with anti-DAF MAb. Peripheral blood was diluted 10 times with PBS. 10 Ml of the diluted blood (-5 x 106 erythrocytes) was incubated with 10 Ml of mouse anti-DAF MAb (Wako Pure Chemical Industries, Osaka, Japan) at 4°C for 30 min and labeled with fluorescein-conjugated goat antimouse IgG (Sigma Chemical Co., St. Louis, MO). Cells were then analyzed by laser cytofluorometry (FACStar, Becton Dickinson Laboratories, Mountain View, CA) (28).
Results
Population ofDAF-negative erythrocytes. To estimate the population of abnormal erythrocyte clones in peripheral blood of PNH patients, we took DAF-negative erythrocyte population analyzed by FACS with anti-DAF MAb. The results of immunofluorescence staining of erythrocytes are summarized in Table I . Patient 1 showed an extremely high population of DAF-negative erythrocytes because her C9 deficiency prevented massive hemolytic attacks. Patient 2 had a moderately high population of DAF-negative cells. Neither of them received any blood transfusions. On the other hand, patients 3 and 4 had massive hemolytic exclusion of PNH erythrocytes and received frequent transfusions of erythrocytes from healthy donors. However, both of them showed moderately low populations of DAF-negative erythrocytes. Patients 5, 6, and 7 were clinically mild. The latter two showed very low populations of DAF-negative erythrocytes. Thus, all of the seven patients were classified into three groups on the basis of clinical features and DAF-negative erythrocyte populations: group I (patients 1 and 2); group II (patients 3 and 4); group III (patients 5, 6, and 7).
Altered expression of gangliosides in PNH erythrocytes. Gangliosides from control erythrocytes showed four major bands (a, b, c, and g in Fig. 1 , lane C > 70% of the total lipid-bound sialic acid) and five minor bands (d, e, f h, and i in Fig. 1, lane C) . Variable expression of gangliosides in PNH erythrocytes was observed. Patient group I (Fig. 1, lanes I and  2) showed dramatic changes in ganglioside expression: deficiency in band g, which was located between the reference gangliosides GD1. and GDIb; and disappearance ofgangliosides more polar than band g on TLC plates. These changes were also demonstrated by TLC densitometry (I in Fig. 2 other hand, the erythrocytes in group III (Fig. 1 , lanes 5-7) had both band g and polar gangliosides, which were not detected in group I. However, the highly polar gangliosides showed variable expression among the three patients ofgroup III. In group II (Fig. 1, lanes 3 and 4) , both gangliosides g and h of the polar gangliosides clearly appeared in patient 3, and g in patient 4. The other highly polar gangliosides, which variably appeared in group III, were not detected in group II. The ganglioside pattern was confirmed using a TLC densitometer (Fig. 2) (24) or preparative TLC (14) . Homogeneity and mobility of isolated g were confirmed by TLC (Fig. 3, lane 3) . After neuraminidase treatment, g was converted to resorcinol-negative, but orcinol-positive neutral glycolipid (Fig. 3, lane 4) that had the same mobility as nLc4Cer (Fig. 3, lane 2) . Sequential treatment with the diplococcal fl-galactosidase, which cleaved Galfl-4 but not Galfl1-3 linkage, yielded a neutral glycolipid (indicated by top arrow in Fig. 3, lane 6 ) that migrated on TLC plate in a manner similar to Lc3Cer derived from IV3NeuAc-nLc4Cer of human erythrocytes (Fig. 3, lane 5) , indicating that the structure is nLc4Cer with sialic acid at the nonreducing terminal. Moreover, both ganglioside g (Fig. 3, lane 6 ) and reference IV3NeuAc-nLc4Cer from human erythrocytes (Fig.   3 , lane 5) gave the same products when analyzed by TLC after sequential enzymatic hydrolysis (Fig. 3 B) .
TLC immunostaining with Y916 MAb showed positive staining of ganglioside g (Fig. 4 , lane 2) as well as the control IV6NeuAc-nLc4Cer from human meconium (Fig. 4 , lane 1) (21) . Differences in mobility on TLC plates may be due to the structural difference in their ceramide moieties. Neuraminidase-treated band g (Fig. 4 , lane 6) migrated to the position identical to that of nLc4Cer (Fig. 4 , lane 5) among reference glycolipids with four carbohydrates on TLC plates (Fig. 4 B) .
HMST-1 MAb, which recognized Lc4Cer, did not react with the neutral glycolipid derived from g after neuraminidase treatment (Fig. 4, lane 10) sialic acid, and major gangliosides in erythrocytes (Table III) . IV3NeuAc-Gg4Cer (GMIb), respectively (data not shown). They were also previously designated as G1, G2, and G5, respectively (14) . Interestingly, the structural difference in sugar moieties between gangliosides b and g was a sialosyl linkage alone. Hence, to examine whether the ceramide moiety defines the carbohydrate determinants (29), we analyzed the ceramide structures of both bands b and g from normal erythrocytes. As a result, band b had a longer chain of fatty acids as compared with that of band g, while there was no difference in the composition of long chain bases between them (Table II) .
Contents of membrane constituents. We also determined the quantities of protein, lipid-bound phosphorus, lipid-bound In all seven PNH patients we found marked changes in the expression of gangliosides on the erythrocyte membrane. Both a characteristic ganglioside designated as g and highly polar gangliosides, which clearly appeared in normal erythrocytes, variably disappeared from erythrocytes in the peripheral blood of PNH patients. Although we used erythrocytes from peripheral blood without the isolation of PNH clones, biochemical analysis of erythrocytes from patient 1 with a very high population of DAF-negative erythrocytes strongly supported the ganglioside alteration in PNH erythrocytes. These results suggest a new feature of membrane disorders in PNH, i.e., metabolic disorders of membrane glycoconjugates, when taken together with the reported abnormalities of PI (glyceroglycolipid)-anchored proteins like DAF (3, 4) , and non-PI-anchored glycoproteins like CR1 (9) and glycophorin-a (10). Among the altered gangliosides, the most characteristic band g was structurally characterized for both clinical use and for understanding the underlying molecular mechanism of metabolic changes in PNH. Chemical analyses identified IV6NeuAc-nLc4Cer as the plausible structure, which had already been isolated from human erythrocytes and analyzed previously ( 14) . Interestingly, the structural difference between both gangliosides b (IV3NeuAc-nLc4Cer) and g (IV6NeuAc-nLc4Cer) was a sialosyl linkage alone in sugar moieties: NeuAca2-3Gal and NeuAca2-6Gal. Ganglioside b was, however, contained in both PNH and normal erythrocytes, whereas ganglioside g was detected clearly in the normal erythrocytes but variably in the PNH erythrocytes. These results suggest an impaired a2-6 sialylation of glycolipids in PNH erythrocytes. As to the molecular basis of impaired glycosylation of glycolipids, some possible mechanisms are suggested: either quantitative or qualitative changes in the expression of the responsible glycosyltransferase or alteration in the regulatory system of the enzyme activity (30) . These mechanisms are also expected to be operated in erythroid precursors in PNH.
Clarification of the precise mechanisms of impaired glycosylation in PNH may lead not only to disclosure ofthe mechanism of altered expression of other polar gangliosides than g in PNH (Fig. 1) , but also to a clue to the abnormal process involving PI-anchoring of membrane proteins. At present, we have not found a common structure in the precisely determined carbohydrate moieties between IV6NeuAc-nLc4Cer ofhuman erythrocytes and PI glycans, such as DAF of human erythrocytes (31), Thy-l glycoprotein of rat brain (32) (34) .
It is important to clarify the relation between the altered expression of gangliosides and the clinical features of PNH. The effect of membrane gangliosides on complement activation is not yet clear; however, recent reports suggest the importance of sialic acid residue of gangliosides in inhibiting the alternative pathway of complement activation (35, 36) . Moreover, we showed an increase in lipid-bound sialic acid in PNH patients 1 and 2, but no difference in the ratio of lipid-bound sialic acid to lipid-bound phosphorus between control and PNH patients (Table III) . Thus, our results might suggest that the increase in total sialic acid would reflect a functional or structural compensation for the loss of DAF or other PI glycoproteins in PNH erythrocytes. In this respect, it is interesting to examine whether or not the loss of both ganglioside g and highly polar gangliosides in PNH erythrocytes accelerates the alternative pathway. DAF expression and the ganglioside abnormalities, however, did not closely correlate. Considering that the increased sensitivity to complement is simply one aspect of many membrane disorders in PNH erythrocytes (2, 9, 10) , it is likely that the ganglioside alteration in PNH reflects new features of membrane disorders other than the abnormal susceptibility of erythrocytes to complement. For example, impaired sialylation in PNH erythrocytes is similar to the blocked synthesis theory of ganglioside changes in cancer cells or in association with malignant transformation (11, 34) . Taken together with the unusual leukemic conversion of PNH (37, 38) , PNH might share ganglioside alteration as a common phenotypic expression in cell membrane with leukemia.
Concerning the control erythrocytes, we should have analyzed the normal erythrocytes from patients before the onset of the disease. However, the biochemical analysis of erythrocytes from the six healthy donors gave the same pattern of gangliosides on TLC plates (data not shown), irrespective of their different ABO blood groups, which are mainly defined by very small but immunologically sufficient amounts of fucosylated neutral GSL. Our control was representative of the healthy donors and thus was a good reference.
If the change in gangliosides is one of the changes that result from unusual hematopoiesis in PNH patients, it is possible that PNH leukocytes and platelets also have metabolic disorders involving GSL, because PNH is a stem-cell disorder of a clonal nature (1, 39) . Furthermore, it would also be interesting to examine membrane GSL of blood cells in other hemolytic disorders or in PNH-related disorders, such as PNH aplastic anemia syndrome (40) and leukemia evolved from PNH (37, 38) .
